ERBB2 and breast carcinoma: Breast cancer remains an important theranostic target, but despite a long history of molecular targeted therapies (e.g., estrogen receptor downregulators and human epidermal growth factor receptor 2 antagonists), progress on theranostic pairs has been slow (72).